Ocular Therapeutix (OCUL) Tops Q4 EPS by 1c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.37), $0.01 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $505 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• Sun Communities names Ileana McAlary as general counsel and EVP
• Pfizer lung cancer drug misses survival goal in Phase 3 trial